Recurring concern
Inadequate safeguards for access to dangerous drugs
First reported 30 Mar 2015•Latest report 29 Apr 2026
What this concern includes
Includes failures of controls specifically intended to regulate, authorise, supervise, audit or restrict access to dangerous drugs across healthcare, ambulance, pharmacy, online-supply and comparable drug-access settings, including the anchor's insufficient regulatory safeguards and auditing and failures involving unregulated online supply or pharmacy safeguards.
Not included
- Excludes generic regulation, auditing or trust concerns where no dangerous-drug access or control issue is identified.
- Excludes controls for non-drug hazardous items, weapons, chemicals or other substances unless the assertion specifically concerns dangerous drugs or drug supply.
- Excludes clinical prescribing, administration, monitoring or treatment failures where access or supply control is not the unsafe condition.
- Excludes the existing narrower concern concerning access to prescription-only medicines outside regulated prescribing when the assertion is specifically limited to that named prescription-only-medicine supply boundary.
- Reports
- 14
- Individual concerns
- 22
- Date range
- 2015–2026
- Stated actions
- 36
Distinct published reports
A report can raise multiple concerns
First to latest report issue date
Described in published responses
Reports over time
Reports over time
Reports about this concern issued each year.
* 2026 is projected from reports observed to 7 Sep 2026.
Most frequent recipients
Most frequent recipients
Reports about this concern sent to each recipient.
Concerns and responses across reports
Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.
-
Concerns raised2
Insufficient regulatory safeguards and auditing for drugs
Lack of dual authorisation for unlocking drug safes
This report raised 1 other concern. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
No linked response statementsNo respondent-stated action or position is linked to these concerns in the published data.
-
Concerns raised1
Lack of strict control over pentobarbital
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.2
-
Position
Drug classification and scheduling are not matters for the Department of Health.
Stated by Department of Health and Social Care
-
Position
The Advisory Council on the Misuse of Drugs, sponsored by the Home Office, is responsible for recommendations on drug classification and scheduling.
Stated by Department of Health and Social Care
-
Concerns raised2
Lack of regulation of Internet-based drug supply
Ease of access to illicit drug supply through Internet websites
This report raised 3 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.4
-
Action
Monitor online controlled-drug offers and act with industry partners to close websites trading illegally.
Stated by Home Office -
Action
Arrest suspected administrators and vendors involved in online drug marketplaces and illegal drug supply.
Stated by Home Office -
Action
Remove technical infrastructure hosting illegal dark-web marketplaces.
Stated by Home Office
-
Action
Continue operations targeting online marketplaces trading controlled drugs and other illegal commodities.
Stated by Home Office
-
Concerns raised1
Lack of regulation of internet-based drug supply
This report raised 1 other concern. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.5
-
Action
Continue working with internet providers to ensure compliance with drug-control law.
Stated by Home Office -
Action
Examine the Medipk website, liaise with its internet service provider, and secure its closure for unlawful medicine sales.
Stated by Home Office -
Action
Work with international partners to develop responses to overseas controlled-drug supply and emerging threats.
Stated by Home Office
-
Action
Build partnerships with international counterparts to address illegally trading websites identified overseas.
Stated by Home Office -
Action
Work with EU and international regulatory agencies to bring offending websites into legal compliance where possible.
Stated by Home Office
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
-
Position
Existing monitoring, enforcement powers, website closures and international partnerships are considered sufficient to address illegal online drug sales.
Stated by Home Office
Data last updated 7 September 2026